NGEN
NASDAQNervGen Pharma
$2.08
-1.60 (-43.48%)
2026-05-22 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
N/A
P/E Ratio
N/A
52W Low
52W High
$1.50
$6.30
Volume
12.4M
About NervGen Pharma
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclero...
Employees
9
Website
nervgen.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | N/A | N/A% | -$44.1M | -$19.5M |
| 2024 | N/A | N/A% | -$16.7M | -$11.7M |
| 2023 | N/A | N/A% | -$16.9M | -$8.5M |
| 2022 | N/A | N/A% | -$15.3M | -$13.1M |
| 2021 | N/A | N/A% | -$10.1M | -$6.5M |
| 2026 Q1 | N/A | N/A% | -$1.7M | -$8.3M |
| 2025 Q4 | N/A | N/A% | -$31.7M | -$10.1M |
| 2025 Q3 | N/A | N/A% | -$3.0M | -$3.8M |
| 2025 Q2 | N/A | N/A% | -$6.7M | -$2.7M |
| 2025 Q1 | N/A | N/A% | -$2.7M | -$2.9M |
| 2024 Q4 | N/A | N/A% | -$6.0M | -$2.5M |
| 2024 Q3 | N/A | N/A% | -$3.9M | -$4.3M |
| 2024 Q2 | N/A | N/A% | -$5.7M | -$3.1M |